A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study

MLA

Sergio Pagliarini, et al. “A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 Mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study.” Journal of Ophthalmology, vol. 2014, Jan. 2014. EBSCOhost, https://doi.org/10.1155/2014/857148.

APA

Sergio Pagliarini, Stephen Beatty, Blandina Lipkova, Eduardo Perez-Salvador Garcia, Stefaan Reynders, Margarita Gekkieva, Abdelkader Si Bouazza, & Stefan Pilz. (2014). A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. Journal of Ophthalmology, 2014. https://doi.org/10.1155/2014/857148

Chicago

Sergio Pagliarini, Stephen Beatty, Blandina Lipkova, Eduardo Perez-Salvador Garcia, Stefaan Reynders, Margarita Gekkieva, Abdelkader Si Bouazza, and Stefan Pilz. 2014. “A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 Mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study.” Journal of Ophthalmology 2014 (January). doi:10.1155/2014/857148.